Findings

What do systematic reviews say?

103 questions · 109 findings · 11 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 20 · 18.3%GRADE not reported 4 · 3.7%Very low 12 · 11%Low 35 · 32.1%Moderate 28 · 25.7%High 10 · 9.2%

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Minor non‐GI bleeding · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis probably leads to higher minor non‐GI bleeding compared with low molecular weight heparin secondary prophylaxis (moderate certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 2.37 [1.44, 3.89]
2 studies · 1495 participants
Moderate

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

All‐cause mortality · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.94 [0.72, 1.23]
4 studies · 1060 participants
Low

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Recurrent venous thromboembolism · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in recurrent venous thromboembolism compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.63 [0.34, 1.15]
4 studies · 1050 participants
Low